Janssen Pharmaceutica

We are part of the world's largest healthcare company, Johnson & Johnson, and enjoy an international reputation for pharmaceutical innovation and quality. For instance, EPREX , a breakthrough in the treatment of anaemia, has helped hundreds of thousands of patients and achieved sales of more than US$3 billion. And RISPERDAL , an innovative medicine for schizophrenia, won the first-ever International Prix Galien for outstanding pharmaceutical achievement. In this section, we invite you to explore our core competencies, with a special focus on our global R&D efforts led by the Johnson & Johnson Pharmaceutical Research and Development (PRD) and our production and marketing activities. Based in Belgium, Janssen Pharmaceutica was established in 1953 by a young medical doctor, Dr Paul Janssen. Unlike most pharmaceutical companies, it was created not as a subsidiary of a chemical factory but solely with the aim of conducting pharmacological research. The one objective of the company has always been the continuous development of better drugs to improve the quality of life.